Is it reasonable to restart Zopiclone (zopiclone) after discontinuation?

Restarting Zopiclone After Discontinuation

Restarting zopiclone after discontinuation is reasonable and can be done safely, particularly if the initial discontinuation was successful and insomnia symptoms have recurred, though you should approach this with caution regarding the duration of previous use and patient risk factors for dependence.

Key Considerations Before Restarting

Assess the Discontinuation Context

• If previous use was short-term (1-2 weeks): Restarting carries minimal risk since zopiclone can be stopped abruptly after brief use without significant withdrawal symptoms 1
• If previous use was medium to long-term (>2 weeks): More caution is warranted, as the patient may have developed some physiological adaptation

Evaluate Patient Risk Factors

Before restarting, screen for:

• History of substance abuse or psychiatric illness - these patients show higher rates of zopiclone abuse and dependency 2
• Previous withdrawal symptoms - if the patient experienced severe rebound insomnia, anxiety, tremor, palpitations, or seizures during prior discontinuation, this indicates higher risk 2
• Age considerations - older adults (particularly those with cognitive impairment) may experience more adverse effects 3

Evidence on Restarting Safety

Rebound and Withdrawal Profile

The evidence suggests zopiclone has a relatively favorable discontinuation profile compared to benzodiazepines:

• Rebound insomnia occurs but is typically mild: Studies show that while some patients experience deterioration in sleep parameters after zopiclone withdrawal, this is often transient and resolves within 1-2 nights 4, 5
• Lower rebound rates than triazolam: In a large study of 1,507 patients, zopiclone showed significantly lower rebound rates than triazolam (p ≤ 0.001) 4
• No relevant withdrawal symptoms in most patients: Classic studies found zopiclone discontinuation is "not accompanied by rebound effect and relevant withdrawal symptoms" in the majority of users 5

However, there's an important caveat: Treatment non-responders showed higher rebound rates than responders 4. This means if zopiclone didn't work well initially, restarting may lead to more discontinuation problems.

Dependence Potential

• Lower than benzodiazepines but not zero: Prescription-event monitoring suggests zopiclone "does not have a high dependence potential" in non-drug abusers 6
• Case reports exist: There are documented cases of dependency with severe withdrawal symptoms, particularly in patients with prior substance abuse 2
• Duration matters: The FDA label for eszopiclone (zopiclone's S-isomer) notes that "use of benzodiazepines and similar agents may lead to physical and psychological dependence. The risk increases with dose and duration of treatment" 7

Practical Restart Protocol

When Restarting is Most Appropriate

1. Recurrent insomnia after successful initial treatment: If zopiclone worked well initially and was successfully discontinued, but insomnia has returned
2. Short previous treatment duration: Prior use was ≤4 weeks
3. No previous withdrawal issues: Patient tolerated discontinuation without significant rebound or withdrawal symptoms
4. Low-risk patient profile: No history of substance abuse or major psychiatric disorders

Dosing Strategy

• Start at 7.5 mg (standard adult dose) 8, 5
• Plan for short-term use: Limit to 2-4 weeks initially 2, 6
• Consider intermittent dosing: Rather than nightly use, which may reduce tolerance and dependence risk 9

Monitoring During Retreatment

Watch for:

• Tolerance development: Loss of efficacy suggests developing tolerance (though this was not seen in trials ≤4 weeks) 6
• Dose escalation requests: A red flag for developing dependence
• Cognitive or psychomotor effects: Particularly in elderly patients 3
• Bitter taste and dry mouth: Most common side effects (3.6% incidence) 6

Alternative Considerations

The 2017 American Academy of Sleep Medicine guideline emphasizes that "chronic use should be reserved for those individuals for whom CBT is either inaccessible or ineffective" 9. Before restarting zopiclone:

• Reassess for CBT-I availability: Cognitive behavioral therapy produces durable gains that persist after treatment ends, unlike medications 9
• Evaluate contributing factors: Medical, neurological, or psychiatric comorbidities may be perpetuating insomnia 9
• Consider other sleep disorders: Rule out sleep apnea, restless legs syndrome, or circadian rhythm disorders

Common Pitfalls to Avoid

1. Don't restart without reassessing the indication: Insomnia may have resolved or changed character
2. Don't ignore previous treatment response: If zopiclone was ineffective initially, restarting is unlikely to help and may increase rebound risk 4
3. Don't restart in high-risk patients without close monitoring: Those with substance abuse history or psychiatric illness need careful surveillance 7
4. Don't plan for indefinite use: Have a clear treatment endpoint and discontinuation plan from the start 2

Special Populations

Elderly Patients

• Zopiclone showed efficacy in older adults with Alzheimer's disease, producing an 81-minute increase in main nocturnal sleep duration 3
• However, 3 patients discontinued due to intense daytime sedation and worsened agitation 3
• Consider starting at lower doses in frail elderly

Patients with Previous Long-Term Use

• If previous use was ≥1 year or at high doses (≥2/3 maximum), approach restarting with greater caution 1
• These patients may have developed more significant physiological dependence
• Consider whether alternative treatments (CBT-I, other medications) might be more appropriate